Monte Rosa Therapeutics, which only came out of stealth mode in May this year with a $32.5m series A, has closed a $96m series B financing to support the further development of its small-molecule protein degrader pipeline.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?